LAWRENCE, Mass.— NxStage announced CE Mark approval for nocturnal home hemodialysis with the NxStage System One. With CE Mark approval, the NxStage System One is continuing its leadership in home hemodialysis technology. NxStage expects to begin marketing the System One for nocturnal dialysis in countries that recognize the CE Mark approval process in the second half of 2013.
Nocturnal dialysis, performed while the patient is sleeping, usually between three and five nights per week, allows much greater time on dialysis without additional inconvenience to the patient or their family. Dialyzing while sleeping has many benefits, but also unique risks; NxStage's nocturnal indication shows the Company's leadership in safety and ease of use by minimizing those risks to the satisfaction of regulators.
"This is an important milestone for NxStage as it provides another example of our leadership in home hemodialysis," said Jeffrey Burbank, chief executive officer, NxStage Medical, Inc. "This approval gives us the unique ability to offer patients and nephrologists greater therapeutic flexibility and an expanded paradigm for dialysis treatment with the System One."